Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Wednesday, October 8th. Barclays began coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective on the stock. BTIG Research reissued a “buy” rating and set a $56.00 target price on shares of Oruka Therapeutics in a research note on Monday, September 29th. HC Wainwright reduced their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, October 27th. Finally, Guggenheim assumed coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They issued a “buy” rating and a $60.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.00.

Oruka Therapeutics Price Performance

ORKA opened at $27.75 on Friday. The business has a 50 day moving average price of $21.39 and a two-hundred day moving average price of $15.67. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -9.88 and a beta of -0.30. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $29.64.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. Equities analysts expect that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. acquired a new position in Oruka Therapeutics in the 2nd quarter worth approximately $31,000. BNP Paribas Financial Markets grew its position in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at $39,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at $68,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.